Taoping Reports 28.4% Increase in Revenue for the First Six Months of 2024, with EPS of $0.13 Per Diluted Share Compared to a Loss of $1.10 in the Corresponding Period of 2023

Stock Information for China SXT Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About China SXT Pharmaceuticals Inc.

Taoping Reports Full Year 2024 Financial Results
25% YoY Growth in Taoping's 1Q 2025 Total Contract Revenue Value Driven by Continued Strong Demand for AI-Related Products
Taoping Announces Major Cooperation with the Mengla County of Yunan Province; Expected Project Value of US$82.5 Million by 2027
Taoping Receives Nasdaq Minimum Bid Price Requirement Extension
Taoping Signs Non-binding Letter of Intent to Acquire Yunti; Transformational Acquisition Would Substantially Improve Taoping's Annual Revenue, Expand its Addressable Market, and Leverage its Current Portfolio
Alert: 30% YoY Growth in Taoping's July 2024 Total Contract Revenue Value Driven by Strong Demand for AI-Based Products
Taoping Accelerates AI Business Growth with New Order for AI-Powered Smart Terminals
AI-based Business Drives 32% Growth in Taoping's First Half 2024 Total Contract Revenue Value

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.